9,383 Results

Phase III post-hoc analyses of Vyndaqel shows benefits in ATTR-ACT.- Pfizer.

 Added 12 hours ago

Pfizer announced that additional sensitivity and post-hoc analyses from the Tafamidis Phase III Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) study provide further...

Complete Response Letter for Ruconest sBLA for expanded indication in hereditary angioedema.- Pharming.

 Added 12 hours ago

Pharming has received a Complete Response Letter (CRL) from the FDA regarding the supplemental Biologics License Application (sBLA) for Ruconest...

JNJ 42756493 filed with the FDA for metastatic urothelial cancer.- Janssen R&D.

 Added 12 hours ago

Janssen Pharmaceutical announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of JNJ 42756493...

NICE refuses to recommend Kymriah to treat diffuse large B-cell lymphoma.- Novartis

 Added 12 hours ago

The National Institute for Health and Care Excellence (NICE), in a draft ruling, has rejected Kymriah (tisagenlecleucel) for use in...

Pooled data from AMAGINE-2 and AMAGINE-3 studies showed Kyntheum cleared psoriasis more effectively than ustekinumab. Leo Pharma

 Added 12 hours ago

Data presented at the 27th European Academy of Dermatology and Venereology (EADV) in Paris, showed that treatment with LEO Pharma’s...

European Commission approves Ilumetri to treat psoriasis.- Almirall

 Added 12 hours ago

Almirall, S.A. has announced that the European Commission (EC) has approved Ilumetri (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for...

Phase III efficacy study of CAM 2038 meets endpoints in chronic low back pain.- Camurus.

 Added 1 day ago

Camurus announced positive results from a Phase III efficacy study of CAM 2038, weekly and monthly buprenorphine depots, in opioid...

Phase III trial of ZP 4207 meets primary endpoint in severe hypoglycemia in diabetes.- Zealand Pharma.

 Added 1 day ago

Zealand Pharma announced it has achieved primary and key secondary endpoints in the pivotal Phase III trial with ZP 4207...

EMA validates filing of Empliciti + pomalidomide + low-dose dexamethasone to treat multiple myeloma. BMS

 Added 1 day ago

Bristol-Myers Squibb Company announced that the European Medicines Agency (EMA) has validated the Company’s type II variation application for Empliciti...

First successful implantation of the Vitaria System in a patient in the ANTHEM-HFrEF pivotal study to reduce progression of heart failure.- LivaNova

 Added 1 day ago

LivaNova PLC announced the the first successful implantation of the Vitaria System in a patient enrolled in the Autonomic Regulation...

Load more